

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3246159

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
NOVARTIS PHARMA AG	03/02/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	GLAXOSMITHKLINE BIOLOGICALS SA
<b>Street Address:</b>	RUE DE L'INSTITUT 89
<b>City:</b>	RIXENSART
<b>State/Country:</b>	BELGIUM
<b>Postal Code:</b>	1330
<b>PROPERTY NUMBERS Total: 6</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	7576176
Patent Number:	8524251
Patent Number:	8394390
Patent Number:	8398988
Patent Number:	8840907
Patent Number:	8834888
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(610)270-5090
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	610-270-6812
<b>Email:</b>	US_CIPKOP@GSK.com
<b>Correspondent Name:</b>	GLAXOSMITHKLINE
<b>Address Line 1:</b>	709 SWEDELAND ROAD
<b>Address Line 2:</b>	CIP UW2220
<b>Address Line 4:</b>	KING OF PRUSSIA, PENNSYLVANIA 19406
<b>ATTORNEY DOCKET NUMBER:</b>	GW/NOVARTIS
<b>NAME OF SUBMITTER:</b>	ARLENE E CANNON
<b>SIGNATURE:</b>	/Arlene E Cannon/
<b>DATE SIGNED:</b>	03/02/2015

**Total Attachments: 3**

source=Executed\_8a\_Confirmatory Assignment#page1.tif

source=Executed\_8a\_Confirmatory Assignment#page2.tif

source=Executed\_8a\_Confirmatory Assignment#page3.tif

**CONFIRMATORY ASSIGNMENT**

WE, **NOVARTIS PHARMA AG** a company limited by shares duly incorporated in Switzerland under the registered number CHE-106.052.527 and whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland do hereby declare that we are the sole owner of the following US patents.

US 7576176 issued August 18, 2009, entitled "Neisseria Meningitidis Antigens and Compositions"

US 8524251 issued September 3, 2013, entitled "Neisseria Meningitidis Antigens and Compositions"

US 8394390 issued March 12, 2013, entitled "Neisserial Antigenic Peptides"

US 8398988 issued March 19, 2013, entitled "Adjuvanting Meningococcal Factor H Binding Protein"

US 8840907 issued September 23, 2014, entitled "Isolated Protein and Compositions Comprising the Protein" and

US 8834888 issued September 16, 2014, entitled "Adjuvanting Meningococcal Factor H Binding Protein,"

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between **NOVARTIS PHARMA AG** and **GLAXOSMITHKLINE BIOLOGICALS SA**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS PHARMA AG** have assigned the entire right, title and interest in and to said patents including, without limitation, the right to take proceedings and recover damages and obtain all other remedies in respect of past infringements thereof, and the right to claim priority thereto, to **GLAXOSMITHKLINE BIOLOGICALS SA** of Rue de l'Institut 89, 1330 Rixensart, Belgium.

Dated this 2 day of March 2015.

Signed for and on behalf of  
**NOVARTIS PHARMA AG**




---

**Rey Papatheodorou**  
As Attorney

Authorized Official on behalf of  
**NOVARTIS PHARMA AG**

EXECUTION VERSION

Signed for and on behalf of  
**NOVARTIS PHARMA AG**

A handwritten signature in black ink, consisting of a large, stylized 'B' followed by several vertical strokes, written over a horizontal line.

**Bernard Cornuejols**  
As Attorney

Authorized Official on behalf of  
**NOVARTIS PHARMA AG**

Signed for and on behalf of  
**GLAXOSMITHKLINE BIOLOGICALS SA**

---

Authorized Official on behalf of  
**GLAXOSMITHKLINE BIOLOGICALS SA**

Signed for and on behalf of  
NOVARTIS PHARMA AG

---

Authorized Official on behalf of  
NOVARTIS PHARMA AG

Signed for and on behalf of  
GLAXOSMITHKLINE BIOLOGICALS SA

 Elizabeth Planelle Pons

---

Authorized Official on behalf of  
GLAXOSMITHKLINE BIOLOGICALS SA